CBD and Sleep - Research Review
By Avery Martz | Updated August 2026
From the CBD and Sleep Wiki
The Short Answer
Cannabinoids affect sleep, but not in a simple or intuitive way. Sleep is one of the most common reasons people turn to cannabis. But the research does not support many of the claims being made.
THC can help people fall asleep faster, but long-term use is associated with reduced sleep quality and worsening insomnia and anxiety in some populations. Additionally, regular users can develop tolerance to THC over time, requiring larger or more frequent doses to produce the same effects.
CBD follows a different pattern. It is not a sedative. Instead, the evidence suggests that when CBD does improve sleep, it may do so indirectly—particularly through effects on anxiety and arousal. The clinical evidence is limited and mixed, but consistent enough to suggest a role in specific use cases.
CBN, another nonintoxicating cannabinoid derived from hemp, is widely marketed for sleep, but there is very little clinical research supporting those claims. At the same time, many users report strong effects, which we will address separately.
Jump To
- THC and Sleep
- CBD - The Research
- Insomnia
- Restless Leg Syndrome
- Sleep Apnea
- PTSD Related Nightmares
- REM Behavior Disorder
- Narcolepsy
- Dosage
- Safety
- CBN and Sleep
- Real World Observations
- Key Takeaways
The CBD Wiki is Free
No ads. No paywalls. No sponsored content.
Learn More About the Wiki →
Support free cannabis education by shopping with Herbal Edge.
How We Evaluate Evidence
Medical research matters, but it doesn’t tell the whole story. In practice, modern medical practitioners make decisions based on three inputs:
- Research – what the clinical research shows and doesn’t
- Clinical experience – what consistently works or fails in practice
- Patient values – what the patients goals are
This is the foundation of Evidence-Based Medicine. Most sleep advice ignores at least one of these. We apply this same framework when assessing the research from a wellness perspective.
Sleep issues are a good example of why this approach matters. Causes vary widely - anxiety, stress, pain, habit - and the research is often limited or inconsistent. Many interventions are also used “off-label,” meaning outside the condition they were formally studied for.
This review does two things: presents the most relevant research, and interprets it in the context of real-world use.
Read More →
-
Defining Evidence-Based Wellness (Publishing Soon)
The Cannabinoids
In this article we will discuss the cannabinoids THC (tetrahydrocannabinol), CBD (cannabidiol), and CBN (Cannabinol).
THC (tetrahydrocannabinol) is the primary intoxicating compound in cannabis. It is responsible for the “high.”
CBD (cannabidiol) is typically the most abundant cannabinoid in hemp. It is non-intoxicating.
CBN (cannabinol) occurs naturally in hemp in small amounts. While it can be extracted from plant material, most commercial CBN is produced by oxidizing THC under controlled conditions in a lab. CBN is also non-intoxicating.
Learn More →
1. THC and Sleep
THC can reduce the time it takes to fall asleep but comes with tradeoffs. Short-term, THC is associated with reduced sleep latency. However, long-term, the pattern changes.
Regular use is linked to reduced sleep quality, tolerance (requiring higher doses), dependence, and worsening insomnia and stress in some users. Longitudinal data shows cannabis use is associated with increases in both stress and insomnia severity over time.
Systematic reviews show mixed outcomes, with some users improving, but many reporting worse or unchanged sleep. In several long-term datasets, worsening sleep is more common than improvement. This matters because most studies are short-term and do not capture these longer-term consequences.
What this means:
THC can work for some in the short term. But the available evidence does not support it as a long-term solution for sleep and in many cases suggests the opposite.
Learn More →
2. Cannabidiol (CBD)
Mechanism
CBD is not a sedative. It does not act like THC and does not strongly induce sleep directly. Instead, it appears to influence anxiety and arousal systems, particularly serotonin-related pathways.
This suggests that any effect CBD has on sleep may be more likely to occur indirectly through anxiety and arousal rather than direct sedation. CBD does not appear to simply “knock you out” in the way traditional sedatives do.
Evidence
The human evidence for CBD and sleep is limited and mixed but it points in a consistent direction. CBD improves anxiety more reliably than it improves sleep.
Sleep improvements are observed in some studies, but results are inconsistent and often fluctuate over time. There are no large, high-quality trials showing that CBD directly improves sleep. In a 72-patient case series, 79% reported reduced anxiety, while 67% reported improved sleep.
Controlled trials show that even at higher doses (300 mg), CBD does not significantly alter sleep architecture in healthy individuals. This is distinctly different from THC which is known to interfere with sleep quality over time.
At the same time, CBD has repeatedly been shown to reduce anxiety in human models. In one study, a 600 mg dose significantly reduced anxiety during a simulated public speaking task.
What this means:
CBD may improve sleep for some people, potentially through its effects on anxiety and arousal rather than through direct sedation. Available evidence also suggests that CBD does not disrupt normal sleep architecture in the same way associated with THC and alcohol.
Learn More →
- CBD and Anxiety (Publishing Soon)
CBD and Specific Sleep Disorders
Insomnia
One hypothesis for CBD and insomnia is that any benefit may depend on what is causing the sleep disturbance. This is particularly relevant when insomnia occurs alongside conditions such as anxiety or chronic pain.
Subclinical anxiety may also contribute to sleep problems in the general population. This could help explain why some people report improved sleep with CBD even though CBD does not appear to act as a direct sedative.
THC follows a different pattern. It consistently reduces the time it takes to fall asleep, but long-term use is also associated with reduced sleep quality, tolerance, and dependence. Abrupt cessation can temporarily worsen sleep.
In our experience, chronic THC users often report diminishing effects over time and worsening sleep quality. We have not observed the same pattern among customers using THC-free CBD products.
Restless Leg Syndrome
There is very limited human research on CBD for Restless Leg Syndrome (RLS). Two small case series (18 total patients) reported near-complete remission of symptoms with cannabis use.
However, these results were observed with smoked cannabis, which cannot be recommended due to well-established health risks. Whether these findings translate to non-inhaled cannabinoid formulations has not been established. More research is needed to determine whether these effects translate to safer, non-inhaled formulations.
Obstructive Sleep Apnea and Central Sleep Apnea
There is limited early research on cannabinoids for obstructive sleep apnea (OSA) and central sleep apnea (CSA).
Some small human studies have shown promising results. However, these studies primarily involve synthetic cannabinoids that are more similar to THC than CBD. These findings suggest the endocannabinoid system may play a role in sleep apnea through neuromodulatory effects, but this area is not well understood. There is not enough evidence to support the use of CBD or other cannabinoids as a first line treatment for sleep apnea.
Sleep apnea is strongly associated with serious health risks, including cardiovascular disease and increased mortality. If you suspect sleep apnea, medical evaluation and treatment (such as CPAP) should be the first step.
PTSD Related Nightmares
PTSD-related sleep disturbances are associated with dysregulation of multiple systems, including the endocannabinoid system. This provides a plausible mechanism for cannabinoid-based interventions.
Much of the available research in this area involves synthetic cannabinoids such as nabilone, not naturally occurring CBD. Some small studies have shown improvements in insomnia and nightmares, but these findings cannot be directly applied to over-the-counter CBD products.
THC has been shown to improve PTSD-related sleep disturbances in short-term studies, but comes with notable side effects and risks of dependence. Long-term data is limited, and further research is needed to better understand the risks associated with chronic use.
The limited data available on CBD is mixed. Some studies report improvements in sleep disturbances, while others show changes such as increased total sleep time alongside longer sleep onset latency. This variability likely reflects differences in the underlying causes of PTSD-related sleep disturbances.
More research is needed to determine whether CBD has a consistent role in treating PTSD-related sleep issues.
REM Behavior Disorder
Evidence for CBD in REM Behavior Disorder (RBD) is extremely limited. One small case series involving four patients reported improvements in symptoms without notable side effects.
Larger and longer-term studies are needed to determine whether cannabinoids have a meaningful role in treatment.
Narcolepsy
Data on CBD and narcolepsy is limited and inconsistent. Some studies report improvements in sleep quality, while others report worsening outcomes.
These differences may reflect variations in dosing, study design, and small sample sizes. More research is needed to determine whether CBD has a consistent therapeutic role in narcolepsy.
Dosage
Dose is one of the largest disconnects between research and real-world use. Clinical studies frequently use doses of 100–600+ mg while most commercially available products only contain 10–50 mg per serving.
CBD also has a long half-life with repeated use, lasting up to several days in some cases. In other contexts, compounds with long half-lives are often introduced with a “loading dose,” followed by a lower maintenance dose. CBD appears to follow a similar pattern.
There is also evidence of a bell-shaped response curve. Too little produces no effect, and increasing the dose beyond a certain point may not provide additional benefit.
What this means:
Many commercial CBD products are used at doses far below those studied in clinical research. This makes it difficult to compare consumer experiences directly with published studies.
In our experience, consistency matters when evaluating an individual's response. We generally recommend using CBD at least five out of seven days per week during an initial trial rather than drawing conclusions from occasional use.
We have also found that many customers do not report a meaningful response until reaching approximately 75 mg or more, although individual responses vary considerably.
Learn More →
Safety
CBD is generally well tolerated.
It is non-intoxicating, shows no evidence of abuse potential or dependence, and side effects, when they occur, are typically mild. In many cases, side effects are related to other ingredients in a product rather than CBD itself.
A WHO review found no evidence of public health concerns associated with pure CBD use.
At higher doses, CBD may interact with medications metabolized by the CYP450 enzyme system. Drugs of concern include blood thinners such as warfarin and Eliquis.
Clinically significant CBD-drug interactions appear to be uncommon, but the available data remains limited. If you are taking prescription medications, it is best to consult a qualified healthcare provider who has experience with CBD in a clinical setting before taking CBD.
Most concerns around CBD safety relate to product quality and labeling accuracy, not the compound itself. This is why we independently verify products focusing on enforcing good manufacturing practices, labeling accuracy, and third-party testing.
Learn More →
- CBD Safety & Considerations (Publishing Soon)
3. Cannabinol (CBN)
CBN is widely marketed as a sleep aid, but there is very little clinical evidence supporting those claims.
A systematic review of human studies found the available research to be limited, outdated, and based on small sample sizes. There are no modern trials using validated sleep measurements.
There is insufficient evidence to support sleep-related claims for CBN based on current clinical data, but that data alone does not capture the whole body of evidence available to us.
A lack of evidence is not the same as evidence of no effect. The research simply has not been done. That gap between clinical research and real-world use is where things get more interesting.
Real World Observations
The clinical evidence for CBN and sleep is limited. That’s clear. But it’s also incomplete.
CBN has developed a strong reputation among users as a sleep-supporting compound—stronger, in many cases, than most over-the-counter supplements marketed for the same purpose. Many individuals report that CBN-containing products are among the most effective tools they’ve used.
That does not replace clinical evidence. But it also should not be ignored.
There is a long precedent for this pattern. Many modern pharmaceuticals began as widely used compounds with consistent real-world effects before being formally studied.
CBD presents a similar, although better-studied, example. Clinical evidence for sleep remains limited, while evidence involving anxiety is considerably stronger. Some sleep studies also report improvement, although the results are inconsistent.
Our customer experience adds another layer of evidence. Over years of working with CBD users, we have repeatedly heard positive reports involving both CBD and CBD+CBN formulations, particularly from people whose sleep difficulties they associate with stress, anxiety, discomfort, or difficulty winding down.
Negative reports are informative too. When customers tell us CBD made little difference, several patterns recur: the amount used was very small, use was inconsistent, or the reason for poor sleep did not appear related to anxiety or arousal. These observations cannot establish causation, but they help generate hypotheses that can be compared against the clinical evidence.
That distinction matters. Clinical research does not currently establish CBD or CBN as treatments for insomnia or other sleep disorders. At the same time, the combination of preliminary research, established pharmacology, and recurring real-world observations provides enough signal to justify continued investigation—and for consumers to make informed decisions about whether these compounds fit their own wellness goals.
Learn More →
Bottom Line
CBD and CBN are not established first-line treatments for insomnia or other sleep disorders, and neither works consistently for everyone.
CBD has substantially more human research behind it than CBN, particularly in areas involving anxiety and arousal. CBN presents a different problem: clinical evidence remains sparse despite unusually consistent reports from people who use it.
Taken together, the evidence is promising but incomplete. CBD and CBN are non-intoxicating in THC-free formulations, generally well tolerated, and show enough signal in both research and real-world use to justify further investigation.
For people exploring cannabinoids for sleep, the important question isn't whether CBD or CBN has been proven to “treat insomnia.” It hasn't. The more useful question is what the evidence actually supports, where customer experience adds information, and where uncertainty remains.
Key Takeaways
What we know
THC, CBD, and CBN affect sleep differently. THC can reduce sleep latency in the short term but is associated with tolerance, dependence, and worsening sleep outcomes with chronic use. CBD is not a conventional sedative and does not appear to disrupt normal sleep architecture. Clinical research on CBN remains extremely limited.
What the evidence suggests
CBD may improve sleep for some people, particularly when anxiety or arousal contributes to poor sleep, but results are inconsistent. CBN has developed a strong reputation among users despite a lack of modern clinical trials, creating a notable gap between published research and real-world experience.
What we don't know
Research has not established which people are most likely to respond to CBD or CBN, what doses are optimal for sleep, or whether either cannabinoid has a consistent role in specific sleep disorders. Evidence for long-term use remains especially limited.
What this doesn't establish
The evidence reviewed here does not establish CBD, CBN, or any product sold by Herbal Edge as a treatment for insomnia, sleep apnea, PTSD, restless leg syndrome, narcolepsy, REM behavior disorder, or any other medical condition.
Sources
Journal: Neuropsychopharmacology
Study: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment
Authors: Bergamaschi et al., 2011
600mg vs placebo
"Pretreatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in their speech performance, and significantly decreased alert in their anticipatory speech."
"The increase in anxiety induced by the simulation public speaking test on subjects with Social Anxiety Disorder was reduced with the use of CBD, resulting in a similar response as the healthy control."
Journal: Sleep Med Reviews
Study: The effects of cannabinoid administration on sleep: a systematic review of human studies
Authors: Gates et al. 2014
"Findings were mixed and showed various effects of cannabinoid administration on several aspects of sleep. Methodological issues in the majority of studies to date, however, preclude any definitive conclusion."
Journal: Frontiers in Pharmacology
Study: No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects
Author: Linares et al., 2018
300mg vs placebo
"Different from anxiolytic and antidepressant drugs such as benzodiazepines and selective serotonin reuptake inhibitors, acute administration of an anxiolytic dose of CBD does not seem to interfere with the sleep cycle of healthy volunteers."
"Future studies should address the effects of CBD on the sleep-wake cycle of patient populations as well as in clinical trials with larger samples and chronic use of different doses of CBD."
Journal: Frontiers in Pharmacology
Study: A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Author: Miller et al., 2018
"The half-life of cannabidiol was reported between 1.4 and 10.9 h after oromucosal spray, 2-5 days after chronic oral administration, 24 h after i.v., and 31 h after smoking."
"This review highlights the paucity in data and some discrepancy in the pharmacokinetics of cannabidiol, despite its widespread use in humans. Analysis and understanding of properties such as bioavailability and half-life is critical to future therapeutic success, and robust data from a variety of formulations is required."
Journal: The Permanente Journal
Study: Cannabidiol in Anxiety and Sleep: A Large Case Series
Authors: S Shannon et al. 2019
"Anxiety scores decreased within the first month in 57 patients (79.2%) and remained decreased during the study duration. Sleep scores improved within the first month in 48 patients (66.7%) but fluctuated over time. In this chart review, CBD was well tolerated in all but 3 patients."
"Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed."
Journal: Current Psychiatry Reports
Study: Cannabis, Cannabinoids, and Sleep: a Review of the Literature
Authors: K. Babson et al. 2019
"Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair sleep quality long-term. Novel studies investigating cannabinoids and obstructive sleep apnea suggest that synthetic cannabinoids such as nabilone and dronabinol may have short-term benefit for sleep apnea due to their modulatory effects on serotonin-mediated apneas."
Journal: Journal of Clinical Sleep medicine
Study: Cannabis and sleep disorders: not ready for prime time? A qualitative scoping review
Authors: C Amaral et al. 2023
"Cannabis users studied were reported either 73% frequent users or 27% sporadic users. The utilization of cannabis showed improved sleep (21%), worse sleep (48%), mixed results (14%), or no impact at all (17%) in the studies published in the last 5 decades."
Journal: Sleep Med Reviews
Study: Cannabinoids + Sleep (Systematic Review)
Author: Suraev et al., 2020
"A total of 14 preclinical studies and 12 clinical studies met inclusion criteria. Results indicated that there is insufficient evidence to support routine clinical use of cannabinoid therapies for the treatment of any sleep disorder..."
"Promising preliminary evidence provides the rationale for future randomized controlled trials of cannabinoid therapies in individuals with sleep apnea, insomnia, post-traumatic stress disorder-related nightmares, restless legs syndrome, rapid eye movement sleep behavior disorder, and narcolepsy. There is a clear need for further investigations on the safety and efficacy of cannabinoid therapies for treating sleep disorders using larger, rigorously controlled, longer-term trials."
Journal: Cannabis and Cannabinoid research
Study: Cannabinol and Sleep: Separating Fact from Fiction
Authors Jamie Corroon (director of a for profit cannabis clinic) 2021
"A systematic search of PubMed/MEDLINE was performed to evaluate the published evidence. The abstracts of 99 human studies were screened for relevance by the author and reviewed for compliance with the inclusion criteria. The characteristics and principal findings were extracted from eight full-text articles that met inclusion criteria for detailed review."
"Pre-clinical and clinical research investigating the effects of CBN is dated and limited, with the preponderance of human studies occurring in the 1970-1980s with small sample sizes lacking diversity in sociodemographic characteristics."
"...there is insufficient published evidence to support sleep-related claims. Randomized controlled trials are needed to substantiate claims made by manufacturers of cannabis products containing CBN."
Journal: Journal of Sleep Research
Study: Longitudinal associations between insomnia, cannabis use and stress among US veterans
Authors: P Davis et al. 2024
"Perhaps more importantly, our results also point to cannabis use as a catalyst for greater increases in both stress and insomnia severity. Our results suggest there may be both benefits and costs of cannabis use among veterans. Specifically, for veterans who experience chronic sleep problems, perceived stress may become overwhelming, and the benefit of stress reduction from increased cannabis use may come at the cost of increasing insomnia symptomatology."
Journal: Neurotherapeutics
Study: Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders
Authors m Kaul et al. 2021
WHO Critical Review Report on Cannabidiol (CBD) (2018)
"At present no public health problems (e.g. driving under the influence of drugs cases,
comorbidities) have been associated with the use of pure CBD."
About the Author
Before launching Herbal Edge, Avery Martz operated one of Idaho's largest CBD retailers, reviewing products, working with independent makers, and helping hundreds of people learn about CBD.